SALT LAKE CITY, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) today announced that management will present at the 2026 Cantor Global Healthcare Conference and at the H.C. Wainwright 28th Annual Global Investment Conference and host 1x1 investor meetings at both conferences.

2026 Cantor Global Healthcare Conference

Date: September 9, 2026

Time of Presentation: 9:10am ET

Location: New York, NY

Format: Presentation and 1x1 meetings

1x1 Meetings: Please contact your Cantor representative

Webcast: link to webcast

HC Wainwright 28^th Annual Global Investment Conference

Date: September 15th, 2026

Time of Presentation: 1:30pm ET

Location: New York, NY

Format: Presentation and 1x1 meetings

1x1 Meetings: Please contact your H.C. Wainwright representative

Webcast: link to webcast

A webcast of the presentation will be available on the "Events" section of the Clene website or using the webcast links above.

About Clene

Clene Inc., (NASDAQ:CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8^® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8^® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn.

Investor Contact: Kevin Gardner, LifeSci Advisors; kgardner@lifesciadvisors.com; 617-283-2856

Media Contact: Caroline Wagner, FTP; CWagner@ftpadvocacy.com; (267) 294-6563